AUPQ201499A0 - Treatment of inflammatory and malignant diseases - Google Patents

Treatment of inflammatory and malignant diseases

Info

Publication number
AUPQ201499A0
AUPQ201499A0 AUPQ2014A AUPQ201499A AUPQ201499A0 AU PQ201499 A0 AUPQ201499 A0 AU PQ201499A0 AU PQ2014 A AUPQ2014 A AU PQ2014A AU PQ201499 A AUPQ201499 A AU PQ201499A AU PQ201499 A0 AUPQ201499 A0 AU PQ201499A0
Authority
AU
Australia
Prior art keywords
inflammatory
treatment
malignant diseases
malignant
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPQ2014A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unisearch Ltd
Original Assignee
Unisearch Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unisearch Ltd filed Critical Unisearch Ltd
Priority to AUPQ2014A priority Critical patent/AUPQ201499A0/en
Publication of AUPQ201499A0 publication Critical patent/AUPQ201499A0/en
Priority to JP2001515810A priority patent/JP2003506078A/en
Priority to CN00811262A priority patent/CN1382211A/en
Priority to EP00949004A priority patent/EP1206527A1/en
Priority to AU62541/00A priority patent/AU6254100A/en
Priority to IL14794600A priority patent/IL147946A0/en
Priority to CA002380678A priority patent/CA2380678A1/en
Priority to PCT/AU2000/000932 priority patent/WO2001011023A1/en
Priority to ZA200200834A priority patent/ZA200200834B/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
AUPQ2014A 1999-08-04 1999-08-04 Treatment of inflammatory and malignant diseases Abandoned AUPQ201499A0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AUPQ2014A AUPQ201499A0 (en) 1999-08-04 1999-08-04 Treatment of inflammatory and malignant diseases
JP2001515810A JP2003506078A (en) 1999-08-04 2000-08-04 Treatment of inflammatory or malignant diseases using DNAzymes
CN00811262A CN1382211A (en) 1999-08-04 2000-08-04 Treatment of inflammatory or malignant disease using dnazymes
EP00949004A EP1206527A1 (en) 1999-08-04 2000-08-04 Treatment of inflammatory or malignant disease using dnazymes
AU62541/00A AU6254100A (en) 1999-08-04 2000-08-04 Treatment of inflammatory or malignant disease using dnazymes
IL14794600A IL147946A0 (en) 1999-08-04 2000-08-04 Treatment of inflammatory or malignant disease using dnazymes
CA002380678A CA2380678A1 (en) 1999-08-04 2000-08-04 Treatment of inflammatory or malignant disease using dnazymes
PCT/AU2000/000932 WO2001011023A1 (en) 1999-08-04 2000-08-04 Treatment of inflammatory or malignant disease using dnazymes
ZA200200834A ZA200200834B (en) 1999-08-04 2002-01-30 Treatment of inflammatory or malignant disease using dnazymes.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPQ2014A AUPQ201499A0 (en) 1999-08-04 1999-08-04 Treatment of inflammatory and malignant diseases

Publications (1)

Publication Number Publication Date
AUPQ201499A0 true AUPQ201499A0 (en) 1999-08-26

Family

ID=3816194

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPQ2014A Abandoned AUPQ201499A0 (en) 1999-08-04 1999-08-04 Treatment of inflammatory and malignant diseases

Country Status (8)

Country Link
EP (1) EP1206527A1 (en)
JP (1) JP2003506078A (en)
CN (1) CN1382211A (en)
AU (1) AUPQ201499A0 (en)
CA (1) CA2380678A1 (en)
IL (1) IL147946A0 (en)
WO (1) WO2001011023A1 (en)
ZA (1) ZA200200834B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
DE10346487A1 (en) * 2003-10-02 2005-05-12 Transmit Technologietransfer Process for the preparation of a cell and / or tissue and / or disease phase specific drug
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
CN103243098B (en) * 2013-04-28 2014-10-01 付玉荣 RelA cut and TLR7 active sequence modified locked nucleic acid deoxyribozyme for targeted therapy of tuberculosis and application thereof
CN103555731A (en) * 2013-11-08 2014-02-05 湖南莱拓福生物科技有限公司 Ser536 phosphorylated gene of NF-kB RelA/p65 and use thereof
PT3093022T (en) 2015-05-15 2019-11-11 Sterna Biologicals Gmbh & Co Kg Gata-3 inhibitors for use in the treatment of th2-driven asthma
WO2017087679A2 (en) * 2015-11-17 2017-05-26 Yale University Bacterial proteases targeting the nf-kb transcription factor family
GB201817990D0 (en) * 2018-11-02 2018-12-19 Univ Of Essex Enterprise Limited Enzymatic nucleic acid molecules
TW202346580A (en) * 2022-04-08 2023-12-01 復旦大學 Dnazyme and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807718A (en) * 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
CA2287520C (en) * 1997-04-29 2010-12-14 The Scripps Research Institute Enzymatic dna molecules
WO1999050452A1 (en) * 1998-03-27 1999-10-07 Johnson & Johnson Research Pty. Limited Catalytic nucleic acid-based diagnostic methods
KR20010072475A (en) * 1998-08-13 2001-07-31 추후제출 DNAzymes and methods for treating restenosis
AU5298699A (en) * 1998-08-13 2000-03-06 Johnson & Johnson Research Pty. Limited Dnazymes and methods for treating hpv-related disorders
AUPP810399A0 (en) * 1999-01-11 1999-02-04 Unisearch Limited Catalytic molecules

Also Published As

Publication number Publication date
CN1382211A (en) 2002-11-27
JP2003506078A (en) 2003-02-18
WO2001011023A1 (en) 2001-02-15
IL147946A0 (en) 2002-08-14
CA2380678A1 (en) 2001-02-15
ZA200200834B (en) 2003-03-26
EP1206527A1 (en) 2002-05-22

Similar Documents

Publication Publication Date Title
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
AUPQ415899A0 (en) Compositions for and methods of treatment of allergic diseases
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AUPQ201499A0 (en) Treatment of inflammatory and malignant diseases
AU4848200A (en) Intravascular device and methods of manufacture and use
AU3896900A (en) Treatment of pain
AUPQ344799A0 (en) Treatment of respiratory diseases and infections
AU1953701A (en) Methods and compositions for treatment of inflammatory disease
AU2001267404A1 (en) Novel compounds for the treatment of inflammatory and cardiovascular diseases
AU7106300A (en) Treatment of skin disorders
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU4515001A (en) Compositions and methods for locally treating inflammatory diseases
AU3760900A (en) Treatment of menstrual function
AU2001258575A1 (en) Treatment of cancer and neurological diseases
AUPQ367699A0 (en) Treatment of cancer
AU5552400A (en) Treatment of cancer
AU1405001A (en) Treatment of diseases
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
GB9908059D0 (en) Diagnosis and treatment of diseases
AU8049098A (en) Composition and methods for the treatment of inflammatory diseases
AU3735900A (en) Methods of treatment and prevention of restenosis

Legal Events

Date Code Title Description
NAA1 Application designating australia and claiming priority from australian document

Ref document number: 6254100

Country of ref document: AU